BioCentury | Jul 28, 2014
Company News

Nicox, Rapid Pathogen Screening deal

Nicox said it has paid a total of $3 million to RPS in license and option fees and has contributed to half of the development costs of RPS-AP and RPS-OH. Under the amended agreement, Nicox...
BioCentury | Jun 25, 2012
Company News

Nicox, Rapid Pathogen Screening deal

Rapid granted NicOx exclusive, worldwide rights to commercialize several ophthalmic diagnostics.The deal includes AdenoPlus adenoviral conjunctivitis diagnostic and two diagnostics in development - RPS-AP for detecting adenoviral and allergic conjunctivitis and RPS-OH to diagnose ocular herpes....
Items per page:
1 - 2 of 2